Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
Adolescent
Adult
Aged
Carcinogenesis
Child
Cross-Sectional Studies
Feasibility Studies
Female
Fluorodeoxyglucose F18
/ administration & dosage
Humans
Kaplan-Meier Estimate
Longitudinal Studies
Magnetic Resonance Imaging
Male
Middle Aged
Nerve Sheath Neoplasms
/ diagnosis
Neurofibroma, Plexiform
/ diagnosis
Neurofibromatosis 1
/ diagnosis
Positron Emission Tomography Computed Tomography
Prognosis
Prospective Studies
ROC Curve
Young Adult
MPNST
PET
SUVmax
natural history
plexiform neurofibroma
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
01
11
2020
revised:
24
12
2020
accepted:
04
01
2021
pubmed:
9
1
2021
medline:
18
3
2021
entrez:
8
1
2021
Statut:
ppublish
Résumé
The purposes of this study were to re-confirm the usefulness of PET/CT in the differentiation of benignity/malignancy of neurogenic tumors in NF1 patients, and to analyze the natural course of plexiform neurofibroma (pNF) and clarify whether PET/CT is also useful for detecting tumors other than neurogenic tumors. PET/CT was prospectively imaged in 36 NF1 patients. There were 14 malignant peripheral nerve sheath tumors (MPNSTs) in 14 patients, and 54 pNFs in 30 patients. Nine patients had both MPNST and pNF. Maximal standardized uptake value (SUVmax) was significantly higher in MPNST (median 7.6: range 4.1-10.4) (P < .001) compared with that of pNF (median 3.7: range 1.6-9.3). The cut-off value of 5.8 resulted in a sensitivity of 78.6% and specificity of 88.9%. Median age was 29 y, and median maximum tumor diameter was 82 mm in 14 MPNST patients. The 5-y overall survival rate was 46.8%. Three patients with low-grade MPNST were alive without disease at the time of this report. In 9 patients in which pNF and MPNST co-existed, 2 showed a higher SUVmax of pNF than that of MPNST. Natural history analysis of pNF (n = 43) revealed that no factors significantly correlated with increased tumor size. Nine lesions other than neurogenic tumors were detected by PET/CT including 5 thyroid lesions and 3 malignant neoplasms. This study revealed the usefulness and limitation of PET/CT for NF1 patients. In the future, it will be necessary to study how to detect over time the malignant transformation of pNF to MPNST, via an intermediate tumor.
Identifiants
pubmed: 33415792
doi: 10.1111/cas.14802
pmc: PMC7935790
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1114-1122Subventions
Organisme : The National Cancer Center Research and Development Fund
ID : 29-A-3
Informations de copyright
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Cancer. 2016 Mar;56:77-84
pubmed: 26824706
J Cancer Res Clin Oncol. 2010 Dec;136(12):1869-80
pubmed: 20229272
Neuro Oncol. 2018 Nov 12;20(12):1643-1651
pubmed: 29718344
Ann Oncol. 2008 Feb;19(2):390-4
pubmed: 17932395
AJNR Am J Neuroradiol. 2014 Aug;35(8):1615-20
pubmed: 24763412
AJR Am J Roentgenol. 2007 Oct;189(4):928-35
pubmed: 17885067
Eur J Surg Oncol. 2003 Aug;29(6):536-41
pubmed: 12875862
Genes Chromosomes Cancer. 2011 Dec;50(12):1021-32
pubmed: 21987445
Arch Neurol. 1988 May;45(5):575-8
pubmed: 3128965
Anticancer Res. 2013 Jun;33(6):2597-604
pubmed: 23749914
Oncologist. 2014 Feb;19(2):193-201
pubmed: 24470531
J Nucl Med. 2015 Mar;56(3):379-85
pubmed: 25655626
Ann Surg Oncol. 2012 Mar;19(3):878-85
pubmed: 21861229
Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1845-1852
pubmed: 28589254
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):776-787
pubmed: 30535768
J Clin Oncol. 2016 Jun 10;34(17):1978-86
pubmed: 26926675
Cancer. 1986 May 15;57(10):2006-21
pubmed: 3082508
Hum Pathol. 2017 Sep;67:1-10
pubmed: 28551330
Neuro Oncol. 2018 May 18;20(6):818-825
pubmed: 29409029
Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60
pubmed: 9788415
Pediatr Blood Cancer. 2018 Jan;65(1):
pubmed: 28771999
PLoS One. 2014 Feb 06;9(2):e85954
pubmed: 24516522
AJR Am J Roentgenol. 2010 Jun;194(6):1568-74
pubmed: 20489098
Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):428-32
pubmed: 16404595
Int J Surg Oncol. 2016;2016:6162182
pubmed: 28058117
J Neurosurg. 2019 Oct 25;:1-11
pubmed: 31653805
Cancer. 2010 Jan 15;116(2):451-8
pubmed: 19924789
Neuro Oncol. 2020 Sep 29;22(9):1368-1378
pubmed: 32152628
J Surg Oncol. 2014 Dec;110(7):813-6
pubmed: 25111615
Cancer Sci. 2021 Mar;112(3):1114-1122
pubmed: 33415792
Arch Pathol Lab Med. 2006 Oct;130(10):1448-53
pubmed: 17090186
J Med Genet. 2002 May;39(5):311-4
pubmed: 12011145
J Clin Oncol. 2005 Nov 20;23(33):8422-30
pubmed: 16293873
Eur Radiol. 2021 Mar;31(3):1548-1557
pubmed: 32894357
Cancer Res. 2002 Mar 1;62(5):1573-7
pubmed: 11894862
Nucl Med Commun. 2018 Nov;39(11):961-968
pubmed: 30106798
Eur Thyroid J. 2018 Jun;7(3):155-161
pubmed: 30023349
J Cancer Res Clin Oncol. 2009 Jul;135(7):891-900
pubmed: 19101731
J Neurooncol. 2012 Jul;108(3):469-75
pubmed: 22407214